Literature DB >> 20524930

Aurora A and B kinases--targets of novel anticancer drugs.

Silvana Libertini1, Antonella Abagnale, Carmela Passaro, Ginevra Botta, Giuseppe Portella.   

Abstract

The Aurora Kinases are highly related serine-threonine kinases, essential for accurate and equal segregation of genomic material during mitosis. A large number of studies have linked the aberrant expression of Aurora kinases to cancer, leading to the development of specific Aurora kinases inhibitors. Several small molecules inhibit with a similar efficacy both Aurora A and Aurora B, however, in most cases the effects resemble Aurora B disruption by genetic methods, indicating that Aurora B represents an effective therapeutic target. These drugs are currently under preclinical or clinical evaluation and are reviewed in this article. The relevant patents are discussed.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20524930     DOI： 10.2174/157489210791760517

Source DB:  PubMed          Journal:  Recent Pat Anticancer Drug Discov        ISSN： 1574-8928            Impact factor:   4.169


  7 in total

1.  Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from nonparenchymal cells.

Authors:  Chad N Brocker; Jiang Yue; Donghwan Kim; Aijuan Qu; Jessica A Bonzo; Frank J Gonzalez
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-01-12       Impact factor: 4.052

2.  Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.

Authors:  Matthew P Martin; Yunting Luo; Roberta Pireddu; Hua Yang; Harsukh Gevariya; Harshani R Lawrence; Sevil Ozcan; Jin-Yi Zhu; Robert Kendig; Mercedes Rodriguez; Roy Elias; Jin Q Cheng; Saïd M Sebti; Ernst Schonbrunn; Nicholas J Lawrence
Journal:  J Med Chem       Date:  2012-08-30       Impact factor: 7.446

3.  Regulation of AURKC expression by CpG island methylation in human cancer cells.

Authors:  Satoshi Fujii; Vibhuti Srivastava; Apurva Hegde; Yutaka Kondo; Lanlan Shen; Koyu Hoshino; Yvette Gonzalez; Jin Wang; Kaori Sasai; Xiaotu Ma; Hiroshi Katayama; Marcos R Estecio; Stanley R Hamilton; Ignacio Wistuba; Jean-Pierre J Issa; Subrata Sen
Journal:  Tumour Biol       Date:  2015-05-20

Review 4.  Current and future trials of targeted therapies in cutaneous melanoma.

Authors:  Matthew S Evans; Subbarao V Madhunapantula; Gavin P Robertson; Joseph J Drabick
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

5.  Targeting glioma cells by antineoplastic activity of reversine.

Authors:  Camila Hirakata; Keli Lima; Bruna Oliveira De Almeida; Lívia Bassani Lins De Miranda; Katharine Gurgel Dias Florêncio; Luciana Costa Furtado; Leticia Veras Costa-Lotufo; João Agostinho Machado-Neto
Journal:  Oncol Lett       Date:  2021-06-15       Impact factor: 2.967

6.  Specificity rendering 'hot-spots' for aurora kinase inhibitor design: the role of non-covalent interactions and conformational transitions.

Authors:  Preethi Badrinarayan; G Narahari Sastry
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

7.  Gene expression of Aurora kinases in prostate cancer and nodular hyperplasia tissues.

Authors:  Emmanuel Nna; Jonathan Madukwe; Ejike Egbujo; Chris Obiorah; Charles Okolie; Godwin Echejoh; Amina Yahaya; James Adisa; Ijeoma Uzoma
Journal:  Med Princ Pract       Date:  2012-10-13       Impact factor: 1.927
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.